Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ruxolitinib phosphate works in reducing fatigue in
patients with chronic lymphocytic leukemia. Ruxolitinib phosphate may stop the growth of
cancer cells by blocking a protein called Janus kinase (JAK) that is needed for cell growth
and may also help control fatigue, decrease the size of lymph nodes and/or lower the number
of chronic lymphocytic leukemia cells in the blood.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Incyte Corporation National Cancer Institute (NCI)